Inogen Company Leadership
| INGN Stock | USD 7.17 0.10 1.41% |
Inogen employs about 766 people. The company is managed by 20 executives with a total tenure of roughly 18 years, averaging almost 0.0 years of service per executive, having 38.3 employees per reported executive. Analysis of Inogen's management performance can provide insight into the firm performance.
| Bart Sanford President Executive Vice President Operations |
Inogen Management Team Effectiveness
The company has return on total asset (ROA) of (0.0778) % which means that it has lost $0.0778 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1896) %, meaning that it created substantial loss on money invested by shareholders. Inogen's management efficiency ratios could be used to measure how well Inogen manages its routine affairs as well as how well it operates its assets and liabilities.Inogen Workforce Comparison
Inogen Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 25,107. Inogen holds roughly 766 in number of employees claiming about 3% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13. Inogen Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inogen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kevin Smith over a month ago Acquisition by Kevin Smith of 28333 shares of Inogen subject to Rule 16b-3 | ||
Kevin Smith over a month ago Disposition of 13700 shares by Kevin Smith of Inogen at 8.33 subject to Rule 16b-3 | ||
Glezer Stanislav over two months ago Acquisition by Glezer Stanislav of 43993 shares of Inogen subject to Rule 16b-3 | ||
Kevin Smith over two months ago Acquisition by Kevin Smith of 11709 shares of Inogen at 8.5614 subject to Rule 16b-3 | ||
Nabil Shabshab over two months ago Disposition of 2117 shares by Nabil Shabshab of Inogen subject to Rule 16b-3 | ||
Ramade Gregoire over three months ago Disposition of 12942 shares by Ramade Gregoire of Inogen at 9.71 subject to Rule 16b-3 | ||
Jason Somer over six months ago Disposition of 3 shares by Jason Somer of Inogen at 8.3 subject to Rule 16b-3 | ||
Kevin Smith over six months ago Insider Trading |
Inogen Notable Stakeholders
An Inogen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inogen often face trade-offs trying to please all of them. Inogen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inogen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Alison Bauerlein | Co-Founder, CFO, Principal Accounting Officer, Executive VP of Fin., Treasurer and Secretary | Profile | |
| Bart Sanford | Executive Vice President Operations | Profile | |
| Michael Sergesketter | Chief President | Profile | |
| Michael Bourque | CFO VP | Profile | |
| Michael CPA | CFO VP | Profile | |
| Jason Somer | General VP | Profile | |
| Nabil Shabshab | Pres CEO | Profile | |
| Vijay Paliwal | Senior Enablement | Profile | |
| Adrien Mithalal | Senior Development | Profile | |
| Agnes Lee | VP Planning | Profile | |
| Philip Corrin | Senior Chain | Profile | |
| Jennifer Boyer | Executive Officer | Profile | |
| Krishna Jhaveri | Chief Officer | Profile | |
| Kevin Smith | General Development | Profile | |
| MBA MD | Executive Officer | Profile | |
| George Parr | Ex Officer | Profile | |
| Matthew Pigeon | Investor Officer | Profile | |
| Kristin Caltrider | CFO VP | Profile | |
| Grgoire Ramade | Executive Officer | Profile | |
| Paul Andreassi | Senior Affairs | Profile |
About Inogen Management Performance
The success or failure of an entity such as Inogen Inc often depends on how effective the management is. Inogen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inogen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inogen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. Inogen operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1021 people.
Inogen Workforce Analysis
Traditionally, organizations such as Inogen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inogen within its industry.Inogen Manpower Efficiency
Return on Inogen Manpower
| Revenue Per Employee | 438.3K | |
| Revenue Per Executive | 16.8M | |
| Net Loss Per Employee | 46.9K | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 142K | |
| Working Capital Per Executive | 5.4M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inogen. If investors know Inogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inogen Inc is measured differently than its book value, which is the value of Inogen that is recorded on the company's balance sheet. Investors also form their own opinion of Inogen's value that differs from its market value or its book value, called intrinsic value, which is Inogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inogen's market value can be influenced by many factors that don't directly affect Inogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.